
The UK competition watchdog is going to ask Brussels for full control over the review of the proposed £31 billion (US$38.7 billion) merger between Virgin Media and telecom operator O2, kicking off what is expected to be a fierce battle over which authority gets the ultimate say on the transaction.
Brussels will receive a request from the UK’s Competition and Markets Authority (CMA), which will argue that the merger solely affects UK consumers, reported The Financial Times.
“This important merger will only impact consumers in the UK and since any review will likely conclude after the transition period, it is only right for the CMA to request it back now,” the CMA told the FT, referring to the December 31 deadline.
Like any EU competition authority, the UK can seek to oversee merger cases that are concentrated in the country. The Virgin Media and O2 deal, however, crosses size thresholds that allow the Commission to oversee the case, meaning ultimately it is for Brussels to decide whether it wants to claim jurisdiction.
The withdrawal agreement includes provisions for the EU to rule on UK-related mergers, even if the final decision comes after the end of the transition.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas